Stryker Co. (NYSE:SYK) Receives Consensus Rating of “Buy” from Brokerages

Stryker Co. (NYSE:SYK) has been assigned an average rating of “Buy” from the twenty-four research firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and nineteen have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $214.89.

A number of equities analysts have issued reports on SYK shares. Credit Suisse Group upped their target price on Stryker from $232.00 to $237.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. Barclays set a $226.00 target price on Stryker and gave the company a “buy” rating in a research report on Friday, July 26th. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Deutsche Bank upped their target price on Stryker from $181.00 to $208.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Finally, Svb Leerink reaffirmed an “outperform” rating on shares of Stryker in a research report on Wednesday, July 10th.

In other Stryker news, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $186.71, for a total value of $871,188.86. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Bijoy Sagar sold 2,000 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $190.43, for a total value of $380,860.00. Following the completion of the sale, the vice president now directly owns 3,350 shares in the company, valued at $637,940.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,398 shares of company stock worth $4,221,459. Corporate insiders own 7.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its position in Stryker by 0.6% in the first quarter. BlackRock Inc. now owns 25,036,303 shares of the medical technology company’s stock worth $4,945,168,000 after buying an additional 153,391 shares during the period. FMR LLC grew its stake in shares of Stryker by 13.4% in the first quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock worth $1,328,951,000 after purchasing an additional 793,560 shares in the last quarter. Fundsmith LLP grew its stake in shares of Stryker by 1.0% in the first quarter. Fundsmith LLP now owns 5,581,841 shares of the medical technology company’s stock worth $1,102,525,000 after purchasing an additional 52,688 shares in the last quarter. Northern Trust Corp grew its stake in shares of Stryker by 1.2% in the first quarter. Northern Trust Corp now owns 3,903,582 shares of the medical technology company’s stock worth $771,036,000 after purchasing an additional 46,183 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Stryker by 6.5% in the fourth quarter. Geode Capital Management LLC now owns 3,665,205 shares of the medical technology company’s stock worth $573,387,000 after purchasing an additional 224,785 shares in the last quarter. 73.53% of the stock is currently owned by hedge funds and other institutional investors.

NYSE SYK traded down $1.30 on Friday, reaching $211.62. The company had a trading volume of 1,158,861 shares, compared to its average volume of 988,841. The firm’s 50-day moving average is $206.68. Stryker has a 1 year low of $144.75 and a 1 year high of $222.59. The firm has a market capitalization of $78.48 billion, a price-to-earnings ratio of 28.95, a PEG ratio of 2.55 and a beta of 0.85. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 25th. The medical technology company reported $1.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The company had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.60 billion. During the same period in the prior year, the company posted $1.76 EPS. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. As a group, analysts forecast that Stryker will post 8.2 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Friday, September 27th. Stryker’s dividend payout ratio is currently 28.45%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: How Does the Quiet Period Work?

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.